Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02927769
Title A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response (CheckMate 744)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

Hodgkin's lymphoma

Therapies

Brentuximab vedotin + Nivolumab

Bendamustine + Brentuximab vedotin

Age Groups: adult | child
Covered Countries USA | ITA | FRA | ESP | DEU | CAN


No variant requirements are available.